Navigation überspringen
Universitätsbibliothek Heidelberg
Verfasst von:Lipsitch, Marc
 Krammer, Florian
 Regev-Yochay, Gili
 Lustig, Yaniv
 Balicer, Ran D
Titel:SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Verlagsort:England
Verlag:Nature Publishing Group
 Nature Publishing Group UK
Jahr:2022
Fussnoten:ObjectType-Article-1 ; ObjectType-Feature-3 ; ObjectType-Review-2 ; SourceType-Scholarly Journals-1 ; content type line 23
Inhalt:Breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in fully vaccinated individuals are receiving intense scrutiny because of their importance in determining how long restrictions to control virus transmission will need to remain in place in highly vaccinated populations as well as in determining the need for additional vaccine doses or changes to the vaccine formulations and/or dosing intervals. Measurement of breakthrough infections is challenging outside of randomized, placebo-controlled, double-blind field trials. However, laboratory and observational studies are necessary to understand the impact of waning immunity, viral variants and other determinants of changing vaccine effectiveness against various levels of coronavirus disease 2019 (COVID-19) severity. Here, we describe the approaches being used to measure vaccine effectiveness and provide a synthesis of the burgeoning literature on the determinants of vaccine effectiveness and breakthrough rates. We argue that, rather than trying to tease apart the contributions of factors such as age, viral variants and time since vaccination, the rates of breakthrough infection are best seen as a consequence of the level of immunity at any moment in an individual, the variant to which that individual is exposed and the severity of disease being considered. We also address key open questions concerning the transition to endemicity, the potential need for altered vaccine formulations to track viral variants, the need to identify immune correlates of protection, and the public health challenges of using various tools to counter breakthrough infections, including boosters in an era of global vaccine shortages.
ISSN:1474-1733
Titel Quelle:Nature reviews. Immunology
Jahr Quelle:2022
Band/Heft Quelle:22, 1, S. 57-65
DOI:doi:10.1038/s41577-021-00662-4
URL:http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F34876702
 http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fsearch.proquest.com%2Fdocview%2F2616475586
 http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fsearch.proquest.com%2Fdocview%2F2608095323
 http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fpubmed.ncbi.nlm.nih.gov%2FPMC8649989
 DOI: https://doi.org/10.1038/s41577-021-00662-4
Sprache:English
Sach-SW:Coronaviruses
 COVID-19
 COVID-19 - epidemiology
 COVID-19 - immunology
 COVID-19 - prevention & control
 COVID-19 - transmission
 COVID-19 vaccines
 COVID-19 Vaccines - administration & dosage
 COVID-19 Vaccines - immunology
 COVID-19 Vaccines - supply & distribution
 Disease transmission
 Health aspects
 Humans
 Infections
 Measurement
 Medical research
 Medicine, Experimental
 Pharmaceutical industry
 Public health
 SARS-CoV-2 - immunology
 SARS-CoV-2 - pathogenicity
 Severe acute respiratory syndrome
 Severe acute respiratory syndrome coronavirus 2
 Vaccination
 Vaccine efficacy
 Vaccine Efficacy - statistics & numerical data
 Vaccines
Verknüpfungen:→ Sammelwerk


zum Seitenanfang